A closed-book, multiple-choice examination following this article tests your under standing of the following objectives:
Describe the medical indications for the use of extracorporeal membrane oxygenation (ECMO). 2. Identify the complications associated with ECMO. 3. Discuss the outcomes associated with ECMO.
To read this article and take the CNE test online, visit www.ajcconline.org and click "CNE Articles in This Issue." No CNE test fee for AACN members.
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Background Extracorporeal membrane oxygenation (ECMO) is used for critically ill patients when conventional treatments for cardiac or respiratory failure are unsuccessful. Objectives To describe patient and treatment characteristics and discharge outcome for ECMO patients, determine which characteristics are associated with good (survival) versus poor (death before hospital discharge) outcomes, and compare characteristics of patients with cardiac versus respiratory failure indicating ECMO. Methods Single-center, retrospective review of all adult patients treated with ECMO from 2005 through 2009. Results A total of 212 patients received ECMO for cardiac (n = 126) or respiratory (n = 86) failure. Mean age was 51 (SD, 14.5) years; support duration was 135 (SD, 149) hours. Survival to discharge was 33% overall; 50% for respiratory indication and 21% for cardiac indication patients. Patients with poor outcomes were older (53 vs 47 years, P = .007), more likely to require cardiovascular support before ECMO (99% vs 91%; P = .02), and had more transfusions (48 vs 24 units, P = .005) and complications (99% vs 87%; P < .001) than did patients with good outcomes. For cardiac patients, older age was associated with poor outcome (poor, 55 vs good, 48 years; P = .01). For respiratory patients, poor outcome was associated with more ventilator days before ECMO (poor, 6 vs good, 3; P = .01), higher peak inspiratory pressure (poor, 39 vs good, 35 cm H 2 O; P = .02), and lower pulmonary compliance (poor, 19 vs good, 25 mL/cm H 2 O; P = .008). Conclusions Patients with respiratory indications for ECMO experienced better survival than did cardiac patients. Increasing age was associated with poor outcome. Complications, regardless of ECMO indication, were common and associated with poor outcome. (American Journal of Critical Care. 2014; 23:365-377) DISCHARGE OUTCOME IN 
ADULTS TREATED WITH EXTRACORPOREAL MEMBRANE OXYGENATION
Although long recognized as a successful therapy in neonates, 1,2 ECMO has lately been used increasingly in adults as a rescue therapy for acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and severe acute respiratory failure. [1] [2] [3] [4] [5] [6] [7] [8] [9] It has also been used in the treatment of acute cardiac failure due to cardiogenic shock (acute myocardial infarction, ischemic and nonischemic cardiomyopathy, myocarditis, pulmonary embolus, and cardiac arrest) and for postcardiotomy syndromes (failure to wean from cardiopulmonary bypass following cardiac surgery). 1, 2, [10] [11] [12] ECMO is now also used in adults as a rescue therapy to bridge to heart, lung, or heart-lung transplant, as rescue therapy from primary graft dysfunction (PGD) after transplant, and to bridge patients with acute cardiac failure to support with a ventricular assist device. [13] [14] [15] [16] [17] [18] ECMO is effective, but the rates of therapy-related morbidity and mortality are high, and ECMO is associated with significant resource utilization. Given the high-risk, complexity, and cost of care in the face of an expanding list of indications, we sought to evaluate our ECMO care outcomes and determine if any baseline or treatment characteristics were associated with better outcomes.
Our purpose was to (1) describe patient characteristics (demographics, indication, comorbid conditions, physiological variables before ECMO), treatment characteristics (duration, mode, cannulation, transfusion, complications), and outcomes (good outcome is survival to discharge) of the total sample of patients supported with ECMO in a major referral center, (2) determine which characteristics of patients and treatments were associated with a good versus a poor outcome, and (3) determine if the characteristics associated with good versus poor outcome differed between patients with a cardiac versus a respiratory indication for support.
Methods

Setting and Sample
This descriptive study used a retrospective review of all adult patients treated with ECMO in 5 years (from January 1, 2005 to December 31, 2009) at the University of Pittsburgh Medical Center Presbyterian Hospital, a tertiary care and ECMO referral center, and was conducted with approval of the UPMC Quality Improvement Review Committee. Patients were identified from our perfusion services database. Of the 217 patients treated with ECMO within the time frame, 5 patients were excluded (in 2 patients, ECMO flow could not be established; in 2 patients, the ECMO course was less than 1 hour; and in 1 patient with 2 ECMO interventions for different indications in the same hospitalization, the data points were overlapping), leaving a final sample of 212 patients.
Data Collection and Variables of Interest
Electronic medical records were reviewed by the primary investigator (J.G.) for specific characteristics of patients and treatments.
Patient characteristics were variables related to patients at baseline or care before ECMO: E xtracorporeal membrane oxygenation (ECMO) is a rescue therapy to support patients with acutely life-threatening cardiac and/or respiratory dysfunction when conventional therapies fail. During ECMO, blood is continuously circulated extracorporeally via a blood pump, passed through a membrane oxygenator for oxygen uptake and carbon dioxide elimination, and then returned to the patient. This complex system serves only as supportive therapy, allowing time for the heart and lungs to rest, recover, and heal. ECMO use can extend from days to weeks. Recently, trends in using ECMO for longer durations across a broader range of indications have challenged clinicians to respond creatively in meeting the demands of patients undergoing ECMO.
fused during ECMO (packed red blood cells, plasma, platelets, and cryoprecipitate).
ECMO mode and cannulation were determined. Venovenous mode included cannulation techniques routing blood from vein to vein (femoral vein to femoral vein, femoral vein to internal jugular vein, dual-lumen cannulation of the internal jugular vein). Venoarterial mode involved routing blood from vein to artery and included peripheral (femoral vein to femoral artery) or central cannulation. Central cannulation involved drainage cannula sites in the superior or inferior vena cava or right atrium and return cannula sites in the aorta, left atrium, and pulmonary or subclavian arteries.
Complications were determined by reviewing clinical and operative notes, microbiology and electroencephalography reports, ICD-9 admission codes, and autopsy reports if within the ECMO/2-weekafter-ECMO window. Bleeding complications were hemothorax, mediastinal/tamponade, pulmonary/ airway, gastrointestinal, retro/intraperitoneal, hematuria requiring continuous irrigation or procedure, and epistaxis (requiring packing or procedure). Neurological complications were intracranial hemorrhage, stroke (embolic or ischemic), seizure (clinical or electroencephalography note), and encephalopathy. Renal failure was coded if dialysis or renal replacement therapy was initiated. Liver dysfunction and MSOF/shock were coded if noted in clinical notes, autopsy reports, or ICD-9 coding. Arrest included cardiac or respiratory arrest requiring resuscitation, cardiopulmonary resuscitation, or defibrillation, but excluded elective cardioversion. Vascular complications included vessel injury requiring repair, intestinal or limb ischemia, or amputation. Infection included pneumonia (positive culture plus treatment), blood stream infection (positive culture), and mediastinitis (positive culture plus treatment) from clinical note and/or microbiology report.
Outcome was determined by survival to hospital discharge (good outcome), whereas poor outcome was death in hospital or being discharged to terminal hospice care (2 patients). Six-month and 1-year survival after ECMO were recorded.
Analyses
Statistical analyses were performed by using IBM SPSS version 20 (SPSS Inc). Missing data fields were not replaced. Continuous variables were reported as demographics, weight, body mass index (calculated as body weight in kilograms divided by height in meters squared), primary ECMO indication (cardiac or respiratory failure), left ventricular ejection fraction (LVEF), Charlson Comorbidity Index (CCI, Deyo method), mechanical ventilator and blood gas parameters before ECMO (ventilator days, Murray ALI score, pH, ratio of PaO 2 to fraction of inspired oxygen (FIO 2 ), compliance, peak inspiratory pressure, positive endexpiratory pressure, and tidal volume/kg), adjunctive therapies before ECMO for respiratory (bagging, nitric oxide, high-frequency ventilation, proning, neuromuscular blockade) and cardiovascular (pressors, inotropes, intra-aortic balloon pump, ventricular assist device, cardiopulmonary resuscitation/defibrillation) support.
Treatment characteristics were variables related to care needs during ECMO: ECMO hours, venoarterial cannulation (vs venovenous), central cannulation (vs peripheral), transfusion requirement, hospital length of stay, and complications (bleeding, neurological problems, renal failure requiring dialysis, liver dysfunction, multisystem organ dysfunction (MSOF)/ shock, arrest, vascular, and infection) while undergoing ECMO and within 2 weeks after ECMO treatment.
Indications for use of ECMO were categorized as either a primary cardiac failure or a primary respiratory failure. Cardiac indication subgroups were cardiogenic shock (acute myocardial infarction, nonischemic cardiomyopathy, cardiopulmonary resuscitation, pulmonary embolus, myocarditis, ischemic cardiomyopathy), postcardiotomy syndrome, and heart or heart-lung transplant recipients. Respiratory indication subgroups were ARDS (aspiration, pulmonary edema/transfusion-associated lung injury, contusion, pneumonia, hypercapnia), bridge to lung transplant, PGD after lung transplant, and other causes of respiratory failure.
LVEF was determined when available from the medical record, using the study closest to the time before ECMO or within 48 hours after the start of ECMO. The CCI was used to assess comorbidity burden by using the method adapted by Deyo et al, 19 which is based on coding from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9).
19 ICD-9 codes were evaluated for 17 comorbidity categories and scored for each category, then given a cumulative score. CCI scores of 5 or greater have been associated with higher mortality and complications related to comorbidity in hospitalized patients. 20, 21 The Murray ALI score was assigned by the principal investigator according to previously described methods. 22 Transfusion included the total number of blood products trans- 
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Electronic medical records were used to gather data on patient and treatment characteristics.
mean with standard deviation, and continuous variables were compared between outcome groups by using a Student t test (normally distributed data) or a Mann-Whitney U test (for data not normally distributed) as appropriate. Categorical variables were reported as frequencies with percentages, with categorical variables compared between the good and poor outcome groups by using 2 tests or the Fisher exact test as appropriate. All tests were 2-sided, and P less than .05 was considered statistically significant.
Results
Of the 212 eligible ECMO patients in the study interval, 126 had a primary cardiac indication and 86 had a primary respiratory indication. Cardiac indications were cardiogenic shock (n = 55), postcardiotomy syndrome (n = 48), and PGD after heart (n = 19) and heart-lung (n = 4) transplant. Respiratory indications included all-cause ARDS (n = 49), bridge to lung transplant (n = 8), PGD after lung transplant (n = 26), and other causes of respiratory failure (n = 3).
Characteristics of the Total Sample
Characteristics of the total sample of patients (Table 1) indicate that ECMO patients had a mean age of 51 years and were predominantly white (94%) and male (65%). LVEF averaged 41% (SD, 20%). The CCI mean score was 3.66 (SD, 2.0). Mean days of mechanical ventilation before ECMO was 3 (SD, 4), and the Murray ALI score mean was 2.84 (SD, 1.0). Nearly all patients required adjunctive respiratory and cardiovascular supportive therapies before ECMO.
The most common respiratory adjuncts were neuromuscular blockade (77%) and inhaled nitric oxide (39%); the most common cardiovascular adjuncts were inotropes (96%) and pressors (84%), IABP (40%), or cardiopulmonary resuscitation/ defibrillation before ECMO (31%). ECMO treatment characteristics (Table 1 ) indicated a mean ECMO duration of 135 (median, 88) hours and a mean of 40 units of blood products. Sixty-nine percent of patients had venoarterial cannulation (including all the cardiac indication patients), and 43% required central cannulation. More than 95% of patients experienced a complication, the most common being renal failure requiring dialysis (61%), bleeding (58%), MSOF/shock (52%), infection (49%), and neurological problems (47%).
Determination of Characteristics Associated With Poor Versus Good Outcome After ECMO in the Total Sample
Of the 212 patients, 57% were successfully weaned from ECMO, 33% lived to discharge (good outcome), and 28% were alive 1 year after ECMO. Poor outcome (death in hospital) was experienced by 142 patients (67%); 50 were successfully weaned from ECMO but died later in hospitalization, and 92 died while undergoing ECMO. Patient and treatment characteristics were compared between subgroups with poor vs good outcomes ( Table 2) . Patients with poor outcomes were significantly older, had a higher mean Murray ALI score, and required more cardiovascular adjunctive therapies. Significantly more patients with a cardiac indication for ECMO had a poor outcome (70%) compared with only 30% of patients with a respiratory indication (P < .001). Outcome also differed for each detailed indication for ECMO initiation. As shown in Figure  1 , only patients with ARDS or bridge to lung transplant were more likely to have a good than poor outcome; a poor outcome was more prevalent for all other indications. Respiratory indication patients were more likely than cardiac indication patients to be weaned successfully from ECMO (65% vs 51%), survive to discharge (50% vs 21%), and be alive 1 year after ECMO (43% vs 18%). Figure 2 shows the early and late outcome curves for the total sample and for the cardiac and respiratory indication subgroups. Cardiac patients experienced a steeper decline in survival over time than did respiratory patients, most notably between the time of being weaned from ECMO and hospital discharge. Cause of death was predominantly MSOF (64%), neurological problems (16%), and cardiac failure (15%).
When examining ECMO treatment characteristics by outcome status (Table 2) , patients who had a poor outcome had significantly higher transfusion requirements than did patients who had a good outcome, but hospital length of stay was higher in patients who had a good outcome (48 vs 24 days, P < .001). Significantly more patients who had a poor outcome had venoarterial cannulation (75% poor vs 56% good, P = .005) and central cannulation (54% poor vs 21% good, P < .001). Bleeding complications were similar in both poor and good outcome subgroups, but patients who had a poor outcome had significantly higher percentages of all other complications except for infection (39% poor vs 67% good, P < .001).
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Table 2
Comparison of patient and treatment characteristics for patients experiencing poor (n = 142) and good (n = 70) outcomes after extracorporeal membrane oxygenation (ECMO) no need for respiratory adjunctive therapy before ECMO were significantly positively associated with good outcome. In patients with a respiratory indication for ECMO, more days of mechanical ventilation before ECMO and higher peak inspiratory pressures were significantly negatively associated with good outcome.
For treatment characteristics, in the cardiac indication subgroup (Table 3) , patients who had a poor outcome had significantly more transfusions
Determination of Characteristics Associated With Good Versus Poor Outcome on the Basis of Cardiac or Respiratory Indication for ECMO Support
Because patients with cardiac and respiratory failure are not homogeneous with regard to need for ECMO and response to ECMO support, we evaluated these subgroups separately with regard to poor versus good outcome (Table 3) to determine if the characteristics associated with a good outcome might be different in the 2 groups. Of 126 patients who had a cardiac indication, only 21% experienced good outcome, whereas of 86 patients who had a respiratory indication, 50% experienced a good outcome. Age was significantly different in the cardiac subgroup (poor outcome older, P = .01), but not in the respiratory subgroup. LVEF was significantly different only in the cardiac subgroup, with the mean LVEF higher for patients with a poor outcome (35%) than for patients with a good outcome (25%; P=.03). In the respiratory indication subgroup, significant differences were found between outcome groups for ventilator days before ECMO (6.1 days poor vs 2.8 good, P = .01), compliance (19 mL/cm H 2 O poor vs 25 mL/cm H 2 O good, P = .008), and peak inspiratory pressure (39 poor vs 35 cm H 2 O good, P = .02).
We performed multivariate logistic regression analysis for patient characteristics associated with good outcome in each ECMO indication subgroup (Table 4) . Variables significant at P less than .15 in univariate analysis were entered into the model, which controlled for age, sex, and CCI. In patients with a cardiac indication for ECMO, increased age was significantly negatively associated with a good outcome, whereas having a higher PaO 2 /FIO 2 and (46 units poor vs 22 good, P = .02) and a higher prevalence of central cannulation (70% poor vs 37% good, P = .003). In both the cardiac and the respiratory indication subgroups, patients with a good outcome had longer hospital stays than did patients with a poor outcome. In the cardiac indication subgroup, significantly more patients who had a poor outcome experienced any complication, including neurological problems, renal failure, liver dysfunction, MSOF/shock, and vascular issues (all P values < .05), whereas 
Discussion
This report describes the patient and treatment characteristics and outcome of a large cohort of adult ECMO patients from a single center during 5 years and provides insight into what clinicians might expect when providing care for ECMO patients. In this sample, 59% of ECMO patients had a cardiac indication whereas 41% had a respiratory indication for treatment. Overall only a little more than half of patients were successfully weaned from ECMO, but 33% had a good outcome and were discharged alive. Nearly all patients needed adjunctive cardiac and respiratory support therapies before ECMO. The mean ECMO duration was 5.6 days, and transfusion requirements were high.
Nearly all patients experienced some type of complication while being treated with ECMO or within 2 weeks after being weaned off of ECMO. Mechanical ECMO complications were rare and are not reported here. In contrast to most other reports listing only mechanical complications or limiting physiological complications to the ECMO course, we included patients' complications out to 2 weeks after ECMO completion in an effort to reflect the impact of ECMO more accurately and describe the critical care needs of this complex population of patients better.
We noted significant differences in outcome between patients with a cardiac versus a respiratory indication for ECMO. Patients treated with ECMO for a respiratory indication had significantly better outcomes (50% survived to discharge) than did patients who had a cardiac indication (only 21% survived to discharge) and were more likely to experience better 1-year survival as well. This result is consistent with findings from the Extracorporeal Life Support Organization (ELSO) registry report, 2 which describes survival to discharge for adult respiratory and cardiac indication patients as 53% and 33%, respectively. Our findings also corroborate the CESAR trial, a randomized, controlled trial of 180 patients with severe respiratory failure prospectively randomized to conventional management or referred to an ECMO center to be considered for ECMO. In that trial, of 90 patients referred for ECMO consideration, 68 received ECMO, of whom 63% survived to 6 months without disability (vs 47% of those receiving conventional management). 4 In several other studies of ECMO for severe acute respiratory failure or ARDS, 49% to 66% of patients survived to hospital discharge 1, 3, 6, 7, [23] [24] [25] and 55% to 70% survived to ICU discharge. 5, 8 Our findings for survival after a cardiac indication for ECMO are also similar to those reported by significantly more patients in the good outcome group experienced infection. In the respiratory indication subgroup, significantly more patients with poor outcome experienced neurological problems, renal failure, liver dysfunction, MSOF/shock, and arrest (all P values < .05). whereas other reports 1,10,11 on ECMO for cardiac failure describe survival ranging from 29% to 39%. Although our cardiac indication subgroup's survival of 21% was lower than the survival rates in some reports, this may reflect our distribution of causes of the cardiac failure. Of postcardiotomy patients, which comprised 38% of the subgroup, only 8% survived, whereas of our patients with cardiogenic shock, comprising 35% of the subgroup, 31% survived. Thus our high proportion of postcardiotomy patients may have skewed overall survival in this subgroup downward.
We also noted differences in survival in our indication subgroups depending on the causes of respiratory failure. ARDS patients had a 51% survival to discharge, as compared with 42% of our PGD lung transplant recipients. This result is comparable to results in a prior report from our center in a smaller sample (33 patients; 16 lung transplant recipients with PGD and 9 with ARDS) with survival to discharge of 39% 26 and is corroborated in a more recent report 15 from our center on ECMO for adults with PGD after lung transplant, who had a 30-day survival of 56%. Another center reported a 90-day survival of 60% in 15 ECMO patients with PGD after lung transplant, 16 whereas the ELSO registry reports that 42% of 151 adult and pediatric lung transplant recipients with PGD survived to discharge. 14 A number of other factors have been associated with poor outcome in ECMO patients with respiratory failure. More days of mechanical ventilation before ECMO has repeatedly been shown to correlate with worse outcome. Pranikoff et al 27 reported survival rates of 73% to 75% when patients had 4 days or less of mechanical ventilation, whereas survival was only 20% to 25% when patients had 5 days or more of mechanical ventilation. In a number of other studies, researchers found that both greater age and more days of mechanical ventilation were other centers between more transfusion and worse outcome in respiratory ECMO patients. 6 Our patients who had a poor outcome had significantly higher percentages of nearly every complication. Renal failure and bleeding complications are widely reported by others, and our renal failure prevalence is comparable, but our prevalence for bleeding is higher than reported by others. 3, 24 Our higher rate of complications as compared with other centers may be partly explained by our methods (we included complications for the entire ECMO course and up to 2 weeks after ECMO), as well as the lack of common definitions for defining complications between various reports. Our higher infection rate in our patients with a good outcome most likely reflects their longer hospital stay and the fact that infection becomes more likely as the course of care lengthens for survivors.
Limitations
This study had several limitations. Using a sample from a single center's ECMO experience may limit the generalizability of the results. In our retrospective review, data were collected from electronic and paper medical records, which were not designed for the purpose of data collection and may not have yielded as rigorous a report of variables as a prospective trial would have yielded. Specifically, we may have underestimated complications because we detected them via review of patients' charts and ordered therapies, a method that may be subject to provider bias. Finally, the inequality in the numbers of patients in our cardiac and respiratory indication subgroups, and in the numbers of patients with poor and good outcomes, might affect between-group comparisons; equal numbers might have yielded more robust findings. Nevertheless, our findings provide valuable insight into the course of therapy and outcome for a large clinical cohort.
Conclusion
ECMO is offered as a supportive therapy to an expanding population of patients with acutely life-threatening cardiac or respiratory failure. Patients are at high risk for ECMO-related morbidity. Clinicians may anticipate lower survival rates for patients in whom ECMO is initiated for a primary cardiac cause compared with patients in whom ECMO is started because of respiratory failure. Complications are experienced by most of both cardiac and respiratory failure patients treated with ECMO, and patients with poor outcomes associated with worse outcome. 3, 6, 24, 28, 29 In our sample, mean age was significantly greater for patients who had a poor outcome in the total sample and cardiac subgroups, and age remained significantly associated with outcome for the cardiac subgroup in the regression analysis. We found that days of mechanical ventilator support trended higher in patients with a poor outcome (3 days vs 2 days), but was not significantly different between outcome groups either in the total sample or the cardiac subgroup. Notably, in our respiratory subgroup, those with poor outcome had significantly more days of mechanical ventilation before ECMO than did the good outcome group, and in the regression analysis, more days of mechanical ventilation before ECMO was negatively associated with a good outcome.
Our finding that the Murray ALI score for the total sample was higher in the good outcome group is contrary to what we expected, as higher Murray scores (closer to 4) reflect higher risk. However, the Murray score is intended to stratify patients with ARDS and ALI, and it may not have served as a reliable risk tool in our patients with a variety of other indications for ECMO.
We noted higher percentages of patients with poor outcome with the use of each cardiovascular adjunct before ECMO, which most likely reflects that most patients were in critically unstable condition when ECMO was started. We also noted that more transfusions were associated with poor outcome in the total sample and the cardiac subgroup, but the transfusion needs were not significantly different between patients with poor and good outcomes in our respiratory indication subgroup. This finding is in contrast to the association noted by experienced more complications than did patients with good outcomes, adding significant complexity to the care of patients undergoing ECMO. Increasing age was associated with poorer outcome in the total sample and in patients with cardiac indications for ECMO and may have implications for anticipatory guidance. Knowledge of the anticipated course of treatment, outcomes of ECMO therapy, common complications, and patterns of care can provide clinicians with valuable insight into the care and treatment of ECMO patients.
